Second primary colorectal cancer in the era of prevalent screening and imaging
ANZ Journal of Surgery, April 11, 2013
Folic acid supplementation and cancer risk: A meta-analysis of randomized controlled trials
International Journal of Cancer, January 25, 2013
Cancer incidence trends among Asian American populations in the United States, 1990 to 2008
Journal of the National Cancer Institute, July 25, 2013
Work stress and risk of cancer: meta-analysis of 5700 incident cancer events in 116000 European men and women
British Medical Journal, March 1, 2013
Evidence Based Medicine
Economic burden of cancer across the European Union: a population-based cost analysis
The Lancet Oncology, January 2, 2014
Question: True or False: The use of IV bisphosphonates for prevention of skeletal-related events (SREs) is higher in patients with bone metastases due to metastatic breast cancer than in patients with metastatic prostate cancer or metastatic lung cancer.
Question: Brain metastases associated with which cancer have increased the most in the post-docetaxel era?
Question: Which bisphosphonate was the most efficacious in a mixed-treatment meta-analysis for reducing the risk of skeletal-related events (SREs) in patients with metastatic breast or prostate cancer?